The Carrell-Krusen Abstract Selection Committee invites you to submit an abstract for presentation at the 46th Annual Carrell-Krusen Neuromuscular Symposium, to be held February 22-23, 2024.

PLEASE NOTE: Abstract submissions on this site are for consideration of content to be presented at a certified Continuing Medical Education Activity. Per the ACCME Standards of Commercial Support, employees of ineligible companies (i.e. pharmaceutical and/or medical device companies) are restricted from influencing the control of CME program content. As such, employees of ineligible companies may not participate in authoring, co-authoring and/or presenting content that is certified for CME.



General Guidelines

  • Spell out all abbreviated terms at first use
  • Do NOT exceed 300 words or use continuation pages, illustrations or tables.
  • Cases will be discussed with the goal of identifying the diagnosis during the live presentation, as part of the learning activity. As such, the final diagnosis is to be omitted from the title and body of the abstract (please identify in the Diagnosis field for viewing by the Abstract Review Committee and for inclusion in the final conference materials).


  • Content addresses the identification, diagnosis, treatment and/or management of neuromuscular diseases.
  • Abstracts must report work not presented or published prior to the meeting
  • All authors must be listed in space provided (please include a good email address so that they can be easily contacted to complete a CME disclosure form)

Please see table below for presentation category, format and abstract submission content details

Abstract CategoryPresentation FormatAbstract Content
Video/Live Patient15 minute podium presentation (patient assessments pre-recorded or presented on stage)Concise summary of history and physical exam, video demonstrating physical/neurologic findings, lab results, discussion of differential diagnosis and final diagnosis with management/treatment
Scientific/Case Series15 minute podium presentationInclude purpose of study, methods, results and conclusions
Path-Rads and EP10 minute podium presentationInclude brief clinical history/PE, results of electrodiagnostic and histologic studies, DNA analysis and conclusions.


(NOT certified for CME)

Printed Poster (NOT certified for CME)Include purpose of study, methods, results and conclusions


The Abstract Review Committee may change the Abstract category based on the context of submissions, format options available in the schedule and overall goals of the conference. You will be notified of this change upon acceptance of submission.

Selection Criteria:

The abstract selection committee is committed to a rigorous, systematic process to identify presentations that will contribute to the overall goals of the symposium. As such, the evaluation and selection of abstracts will be based on:

  • Clarity of purpose/problem statement
  • Quality of research methods (if applicable)
  • Relevance to medical practice (applicability or advances knowledge in the field)


  • The First Author of accepted abstracts will be notified by email before 12/22/23. All co-authors will be copied on notification.
  • The time allowed for presentations from the platform and posters may vary according to the material presented and the needs of the session and will be determined at time of abstract acceptance.
  • Accepted abstracts will be printed in the Journal of Clinical Neuromuscular Disease.

A panel from the Abstract Selection Committee Awards will identify the best abstract presentations, which will be announced prior to the close of the symposium.


  • In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accrediting Continuing Education, all persons in the position to control the content of an education activity are required to disclose all financial relationships in any amount occurring within the past 24 months with any ineligible company (any entity whose primary business is producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients).  UT Southwestern also considers ineligible those companies producing, marketing, selling, re-selling, or distributing healthcare products in development for future use on patients, such as healthcare product research companies. All reported financial relationships with ineligible companies are reviewed for relevancy and then mitigated through a content review process prior to the activity (where applicable).
  • Upon acceptance of the abstract, ALL authors will be emailed a link to complete an online Financial Relationship Disclosure form.
  • All online disclosure forms must be completed no later than 1/12/24. It is the responsibility of the First Author to ensure all disclosures are submitted by this deadline. Failure to provide this information may result in your abstract being removed from the program.


  • It is the speakers’ responsibility to register for the symposium. Abstract acceptance does not guarantee any type of registration discount.